Evidence map›Paper›PMID 41006686›Full record

ArticleApoptosis : an international journal on programmed cell death2025

Endothelial SPRY1 deficiency associates with angiogenic-metabolic reprogramming in pulmonary arterial hypertension: a multi-omics analysis of bulk and single-cell transcriptomic profiles.

Yanfei Mo, Desheng Wang, Zhenkun Deng, Pingping Zhao, Zhen Gou, Xiaoyun Sun, Yunrui Zhang, Yang Bai

Abstract read
PubMed Publisher
In one paragraph

Article in Apoptosis : an international journal on programmed cell death, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yanfei Mo *Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning, China.
Desheng Wang *Department of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning, China.
Zhenkun DengDepartment of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning, China.
Pingping ZhaoDepartment of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning, China.
Zhen GouDepartment of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning, China.
Xiaoyun SunDepartment of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning, China.
Yunrui ZhangDepartment of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning, China.
Yang BaiDepartment of Clinical Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning, China. ybai@cmu.edu.cn.

Funding

National Natural Science Foundation of China 81803530
6 · The paper itself

Abstract

The mechanism underlying vascular remodeling in pulmonary arterial hypertension (PAH) involves complex interactions among various cell types, with dysregulation of endothelial cells (ECs) homeostasis considered a crucial pathological factor. However, their local cellular changes still need to be fully identified during PAH. This study utilized single-cell RNA sequencing data from the GEO database to analyze lung tissue samples from PAH patients and normal controls, revealing significant heterogeneity in lung ECs and dysregulated metabolic pathways. We identified a significant expansion of capillary ECs in PAH patients, linked to dysregulated angiogenesis and glycolysis-tricarboxylic acid cycle metabolic pathways. Through integrative high-dimensional weighted gene co-expression network analysis (hdWGCNA) and machine learning, we identified SPRY1 as a novel key biomarker in PAH pathogenesis and validated its significant downregulation in a monocrotaline-induced PAH rat model. These findings establish capillary ECs expansion and SPRY1 deficiency as pivotal drivers in PAH pathogenesis, providing a foundation for precise therapeutic targeting.

Indexed as

Endothelial CellsMembrane ProteinsNeovascularization, PathologicPulmonary Arterial HypertensionTranscriptomeAnimalsFemaleGene Expression ProfilingGene Regulatory NetworksHumansLungMaleMetabolic ReprogrammingMultiomicsPhosphoproteinsRatsMembrane ProteinsPhosphoproteinsSPRY1 protein, humanAngiogenesisEndothelial cellsMetabolismPulmonary arterial hypertensionSPRY1

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.